Merit Cudkowicz
Merit Cudkowicz is an expert in Neurology at Massachusetts General Hospital (United States). As of November 2026, ScienceLeadR ranks Merit Cudkowicz in the top 1% of experts worldwide for Amyotrophic Lateral Sclerosis and Proteostasis Deficiencies. Merit Cudkowicz has authored 417 publications, the most recent in 2026, and is an investigator in 48 clinical trials, 1 of them ongoing. SLR score: 2,877 (community average: 125). How the SLR is computed.
LeadR Profile
Neurology
Subspecialties: Internal Medicine - Biochemistry - Cardiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1989 - 2026
Number : 417
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| The Cardiovascular Origins of the Aging Brain. PMID 42954687 — dementia, cardiorespiratory fitness, aging, brain | JACC Adv | 2026 | 0 |
| ALS untangled #83: clenbuterol. PMID 41795667 — muscular atrophy, sclerosis, adrenergic agents, adrenergic agonists, amyotrophic lateral sclerosis, clenbuterol, therapeutics | Amyotroph Lateral Scler Frontotemporal Degener | 2026 | 0 |
| Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. PMID 42716044 — sclerosis, safety, amyotrophic lateral sclerosis, enzymes, nervous system | Lancet Neurol Top journal | 2026 | 1 |
| Integrated Neurology Models for Population Health: Case Studies and Lessons From Academic Health Systems. PMID 42678875 — telemedicine, neurology | Neurol Clin Pract | 2026 | 0 |
| Functional Activity of TDP-43: A Direct Biomarker for ALS. PMID 42645064 — cells, serum, biomarkers, amyotrophic lateral sclerosis | Biosensors (Basel) | 2026 | 0 |
Clinical Studies 48
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| HEALEY ALS Platform Trial Regimen I NUZ 001 NCT07410806 — sclerosis, safety, multiple chronic conditions, amyotrophic lateral sclerosis, appendix | Phase 2/Phase 3 | Active not recruiting | 2026 |
LeadR Networks
Main global connection map